Polyphenols, secondary metabolites of plants, exhibit different anti-cancer and cytoprotective properties such as anti-radical, anti-angiogenic, anti-inflammation, or cardioprotective. Some of these activities could be linked to modulation of miRNAs expression. MiRNAs play an important role in posttranscriptional regulation of their target genes that could be important within cell signalling or preservation of cell homeostasis, e.g., cell survival/apoptosis. We evaluated the influence of a non-toxic concentration of taxifolin and quercetin on the expression of majority human miRNAs via Affymetrix GeneChip™ miRNA 3.0 Array. For the evaluation we used two cell models corresponding to liver tissue, Hep G2 and primary human hepatocytes. The array analysis identified four miRNAs, miR-153, miR-204, miR-211, and miR-377-3p, with reduced expression after taxifolin treatment. All of these miRNAs are linked to modulation of ZEB2 expression in various models. Indeed, ZEB2 protein displayed upregulation after taxifolin treatment in a dose dependent manner. However, the modulation did not lead to epithelial mesenchymal transition. Our data show that taxifolin inhibits Akt phosphorylation, thereby diminishing ZEB2 signalling that could trigger carcinogenesis. We conclude that biological activity of taxifolin may have ambiguous or even contradictory outcomes because of non-specific effect on the cell.

Department of Medical Chemistry and Biochemistry Faculty of Medicine and Dentistry Palacký University 77515 Olomouc Czech Republic

Faculty of Sport Studies Masaryk University 60177 Brno Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacký University 77515 Olomouc Czech Republic

Zobrazit více v PubMed

Marin L., Miguelez E.M., Villar C.J., Lombo F. Bioavailability of dietary polyphenols and gut microbiota metabolism: Antimicrobial properties. Biomed. Res. Int. 2015;2015:905215. doi: 10.1155/2015/905215. PubMed DOI PMC

Grosso G., Stepaniak U., Topor-Madry R., Szafraniec K., Pajak A. Estimated dietary intake and major food sources of polyphenols in the Polish arm of the HAPIEE study. Nutrition. 2014;30:1398–1403. doi: 10.1016/j.nut.2014.04.012. PubMed DOI PMC

Ovaskainen M.L., Torronen R., Koponen J.M., Sinkko H., Hellstrom J., Reinivuo H., Mattila P. Dietary intake and major food sources of polyphenols in Finnish adults. J. Nutr. 2008;138:562–566. doi: 10.1093/jn/138.3.562. PubMed DOI

Hussain T., Tan B., Yin Y., Blachier F., Tossou M.C., Rahu N. Oxidative Stress and Inflammation: What Polyphenols Can Do for Us? Oxid. Med. Cell Longev. 2016;2016:7432797. doi: 10.1155/2016/7432797. PubMed DOI PMC

Rasouli H., Farzaei M.H., Khodarahmi R. Polyphenols and their benefits: A review. Int. J. Food Prop. 2017;20:1700–1741. doi: 10.1080/10942912.2017.1354017. DOI

Tresserra-Rimbau A., Lamuela-Raventos R.M., Moreno J.J. Polyphenols, food and pharma. Current knowledge and directions for future research. Biochem. Pharmacol. 2018;156:186–195. doi: 10.1016/j.bcp.2018.07.050. PubMed DOI

Coppo E., Marchese A. Antibacterial activity of polyphenols. Curr. Pharm. Biotechnol. 2014;15:380–390. doi: 10.2174/138920101504140825121142. PubMed DOI

Gabrielova E., Kren V., Jaburek M., Modriansky M. Silymarin component 2,3-dehydrosilybin attenuates cardiomyocyte damage following hypoxia/reoxygenation by limiting oxidative stress. Physiol. Res. 2015;64:79–91. doi: 10.33549/physiolres.932703. PubMed DOI

Sunil C., Xu B.J. An insight into the health-promoting effects of taxifolin (dihydroquercetin) Phytochemistry. 2019:166. doi: 10.1016/j.phytochem.2019.112066. PubMed DOI

Milenkovic D., Deval C., Gouranton E., Landrier J.F., Scalbert A., Morand C., Mazur A. Modulation of miRNA expression by dietary polyphenols in apoE deficient mice: A new mechanism of the action of polyphenols. PLoS ONE. 2012;7:e29837. doi: 10.1371/journal.pone.0029837. PubMed DOI PMC

Del Follo-Martinez A., Banerjee N., Li X., Safe S., Mertens-Talcott S. Resveratrol and quercetin in combination have anticancer activity in colon cancer cells and repress oncogenic microRNA-27a. Nutr. Cancer. 2013;65:494–504. doi: 10.1080/01635581.2012.725194. PubMed DOI

Dostal Z., Modriansky M. The effect of quercetin on microRNA expression: A critical review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2019;163:95–106. doi: 10.5507/bp.2019.030. PubMed DOI

Gavrilas L.I., Ionescu C., Tudoran O., Lisencu C., Balacescu O., Miere D. The Role of Bioactive Dietary Components in Modulating miRNA Expression in Colorectal Cancer. Nutrients. 2016;8:590. doi: 10.3390/nu8100590. PubMed DOI PMC

Lee R.C., Feinbaum R.L., Ambros V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854. doi: 10.1016/0092-8674(93)90529-Y. PubMed DOI

Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47:D155–D162. doi: 10.1093/nar/gky1141. PubMed DOI PMC

Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. miRBase: Tools for microRNA genomics. Nucleic Acids Res. 2008;36:D154–D158. doi: 10.1093/nar/gkm952. PubMed DOI PMC

Hashimoto Y., Akiyama Y., Yuasa Y. Multiple-to-Multiple Relationships between MicroRNAs and Target Genes in Gastric Cancer. PLoS ONE. 2013:8. doi: 10.1371/journal.pone.0062589. PubMed DOI

Zhang B.H., Pan X.P., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007;302:1–12. doi: 10.1016/j.ydbio.2006.08.028. PubMed DOI

Gebeshuber C.A., Zatloukal K., Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep. 2009;10:400–405. doi: 10.1038/embor.2009.9. PubMed DOI PMC

Jiang H., Zhang G., Wu J.H., Jiang C.P. Diverse roles of miR-29 in cancer (review) Oncol. Rep. 2014;31:1509–1516. doi: 10.3892/or.2014.3036. PubMed DOI

Gonzalez D.M., Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal. 2014;7:re8. doi: 10.1126/scisignal.2005189. PubMed DOI PMC

Vandewalle C., Van Roy F., Berx G. The role of the ZEB family of transcription factors in development and disease. Cell Mol. Life Sci. 2009;66:773–787. doi: 10.1007/s00018-008-8465-8. PubMed DOI PMC

Nieto M.A., Huang R.Y., Jackson R.A., Thiery J.P. Emt: 2016. Cell. 2016;166:21–45. doi: 10.1016/j.cell.2016.06.028. PubMed DOI

Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009;119:1420–1428. doi: 10.1172/JCI39104. PubMed DOI PMC

Chen Z., Tang Z.Y., He Y., Liu L.F., Li D.J., Chen X. miRNA-205 Is a Candidate Tumor Suppressor that Targets ZEB2 in Renal Cell Carcinoma. Oncol. Res. Treat. 2014;37:658–664. doi: 10.1159/000368792. PubMed DOI

Li L.N., Li W.L. Epithelial-mesenchymal transition in human cancer: Comprehensive reprogramming of metabolism, epigenetics, and differentiation. Pharmacol. Ther. 2015;150:33–46. doi: 10.1016/j.pharmthera.2015.01.004. PubMed DOI

Di Gennaro A., Damiano V., Brisotto G., Armellin M., Perin T., Zucchetto A., Guardascione M., Spaink H.P., Doglioni C., Snaar-Jagalska B.E., et al. A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness. Cell Death Differ. 2018 doi: 10.1038/s41418-018-0103-x. PubMed DOI PMC

Long Z.H., Bai Z.G., Song J.N., Zheng Z., Li J., Zhang J., Cai J., Yao H.W., Wang J., Yang Y.C., et al. miR-141 Inhibits Proliferation and Migration of Colorectal Cancer SW480 Cells. Anticancer Res. 2017;37:4345–4352. doi: 10.21873/anticanres.11828. PubMed DOI

Sun Z., Zhang Z., Liu Z., Qiu B., Liu K., Dong G. MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2. Med. Oncol. 2014;31:982. doi: 10.1007/s12032-014-0982-8. PubMed DOI

Chou C.H., Shrestha S., Yang C.D., Chang N.W., Lin Y.L., Liao K.W., Huang W.C., Sun T.H., Tu S.J., Lee W.H., et al. miRTarBase update 2018: A resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46:D296–D302. doi: 10.1093/nar/gkx1067. PubMed DOI PMC

Xiao L., Zhou X., Liu F., Hu C., Zhu X., Luo Y., Wang M., Xu X., Yang S., Kanwar Y.S., et al. MicroRNA-129-5p modulates epithelial-to-mesenchymal transition by targeting SIP1 and SOX4 during peritoneal dialysis. Lab. Investig. 2015;95:817–832. doi: 10.1038/labinvest.2015.57. PubMed DOI PMC

Yue S., Wang L., Zhang H., Min Y., Lou Y., Sun H., Jiang Y., Zhang W., Liang A., Guo Y., et al. miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM. Tumour Biol. 2015;36:6741–6749. doi: 10.1007/s13277-015-3372-8. PubMed DOI

Wang Y.Z., Zhou Y.J., Yang Z.C., Chen B.Y., Huang W.N., Liu Y.Y., Zhang Y. MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer. Tumor Biol. 2017:39. doi: 10.1177/1010428317690998. PubMed DOI

Jiang G.B., Wen L., Deng W.P., Jian Z.Y., Zheng H.M. Regulatory role of miR-211-5p in hepatocellular carcinoma metastasis by targeting ZEB2. Biomed. Pharmacother. 2017;90:806–812. doi: 10.1016/j.biopha.2017.03.081. PubMed DOI

Ye C., Hu Y., Wang J. MicroRNA-377 targets zinc finger E-box-binding homeobox 2 to inhibit cell proliferation and invasion of cervical cancer. Oncol. Res. 2018 doi: 10.3727/096504018X15201124340860. PubMed DOI PMC

Vandewalle C., Comijn J., De Craene B., Vermassen P., Bruyneel E., Andersen H., Tulchinsky E., Van Roy F., Berx G. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 2005;33:6566–6578. doi: 10.1093/nar/gki965. PubMed DOI PMC

Alam M.N., Almoyad M., Huq F. Polyphenols in Colorectal Cancer: Current State of Knowledge including Clinical Trials and Molecular Mechanism of Action. Biomed. Res. Int. 2018;2018:4154185. doi: 10.1155/2018/4154185. PubMed DOI PMC

Bindels S., Mestdagt M., Vandewalle C., Jacobs N., Volders L., Noel A., van Roy F., Berx G., Foidart J.M., Gilles C. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene. 2006;25:4975–4985. doi: 10.1038/sj.onc.1209511. PubMed DOI

Du K., Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J. Biol. Chem. 1998;273:32377–32379. doi: 10.1074/jbc.273.49.32377. PubMed DOI

Conquer J.A., Maiani G., Azzini E., Raguzzini A., Holub B.J. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr. 1998;128:593–597. doi: 10.1093/jn/128.3.593. PubMed DOI

Graefe E.U., Wittig J., Mueller S., Riethling A.K., Uehleke B., Drewelow B., Pforte H., Jacobasch G., Derendorf H., Veit M. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J. Clin. Pharmacol. 2001;41:492–499. doi: 10.1177/00912700122010366. PubMed DOI

Russo M., Spagnuolo C., Tedesco I., Bilotto S., Russo G.L. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochem. Pharmacol. 2012;83:6–15. doi: 10.1016/j.bcp.2011.08.010. PubMed DOI

Rajnochova Svobodova A., Rysava A., Psotova M., Kosina P., Zalesak B., Ulrichova J., Vostalova J. The Phototoxic Potential of the Flavonoids, Taxifolin and Quercetin. Photochem. Photobiol. 2017;93:1240–1247. doi: 10.1111/php.12755. PubMed DOI

Battaglia R.A., Delic S., Herrmann H., Snider N.T. Vimentin on the move: New developments in cell migration. F1000Res. 2018:7. doi: 10.12688/f1000research.15967.1. PubMed DOI PMC

Xia Y., Shen S., Verma I.M. NF-kappaB, an active player in human cancers. Cancer Immunol. Res. 2014;2:823–830. doi: 10.1158/2326-6066.CIR-14-0112. PubMed DOI PMC

McElwee M.K., Song M.O., Freedman J.H. Copper activation of NF-kappaB signaling in HepG2 cells. J. Mol. Biol. 2009;393:1013–1021. doi: 10.1016/j.jmb.2009.08.077. PubMed DOI PMC

Gilles C., Polette M., Mestdagt M., Nawrocki-Raby B., Ruggeri P., Birembaut P., Foidart J.M. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003;63:2658–2664. doi: 10.1136/ijgc-00009577-200303001-00219. PubMed DOI

Razak S., Afsar T., Ullah A., Almajwal A., Alkholief M., Alshamsan A., Jahan S. Taxifolin, a natural flavonoid interacts with cell cycle regulators causes cell cycle arrest and causes tumor regression by activating Wnt/ beta -catenin signaling pathway. BMC Cancer. 2018;18:1043. doi: 10.1186/s12885-018-4959-4. PubMed DOI PMC

Manigandan K., Manimaran D., Jayaraj R.L., Elangovan N., Dhivya V., Kaphle A. Taxifolin curbs NF-kappaB-mediated Wnt/beta-catenin signaling via up-regulating Nrf2 pathway in experimental colon carcinogenesis. Biochimie. 2015;119:103–112. doi: 10.1016/j.biochi.2015.10.014. PubMed DOI

Manning B.D., Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017;169:381–405. doi: 10.1016/j.cell.2017.04.001. PubMed DOI PMC

Carruba G., Cervello M., Miceli M.D., Farruggio R., Notarbartolo M., Virruso L., Giannitrapani L., Gambino R., Montalto G., Castagnetta L. Truncated form of beta-catenin and reduced expression of wild-type catenins feature HepG2 human liver cancer cells. Ann. N. Y. Acad. Sci. 1999;886:212–216. doi: 10.1111/j.1749-6632.1999.tb09419.x. PubMed DOI

Wei W., Jin J., Schlisio S., Harper J.W., Kaelin W.G., Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 2005;8:25–33. doi: 10.1016/j.ccr.2005.06.005. PubMed DOI

Szymonowicz K., Oeck S., Malewicz N.M., Jendrossek V. New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response. Cancers. 2018;10:78. doi: 10.3390/cancers10030078. PubMed DOI PMC

Crawford R.R., Potukuchi P.K., Schuetz E.G., Schuetz J.D. Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions. Drug Metab. Dispos. Biol. Fate Chem. 2018;46:567–580. doi: 10.1124/dmd.118.080663. PubMed DOI PMC

Liao Y., Li H., Pi Y., Li Z., Jin S. Cardioprotective effect of IGF-1 against myocardial ischemia/reperfusion injury through activation of PI3K/Akt pathway in rats in vivo. J. Int. Med. Res. 2019;47:3886–3897. doi: 10.1177/0300060519857839. PubMed DOI PMC

Manning B.D., Cantley L.C. AKT/PKB signaling: Navigating downstream. Cell. 2007;129:1261–1274. doi: 10.1016/j.cell.2007.06.009. PubMed DOI PMC

Zhu Q.S., Rosenblatt K., Huang K.L., Lahat G., Brobey R., Bolshakov S., Nguyen T., Ding Z., Belousov R., Bill K., et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 2011;30:457–470. doi: 10.1038/onc.2010.421. PubMed DOI PMC

Chen X., Gu N., Xue C., Li B.R. Plant flavonoid taxifolin inhibits the growth, migration and invasion of human osteosarcoma cells. Mol. Med. Rep. 2018;17:3239–3245. doi: 10.3892/mmr.2017.8271. PubMed DOI

Li B., Xu W.W., Lam A.K.Y., Wang Y., Hu H.F., Guan X.Y., Qin Y.R., Saremi N., Tsao S.W., He Q.Y., et al. Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget. 2017;8:38755–38766. doi: 10.18632/oncotarget.16333. PubMed DOI PMC

Sieuwerts A.M., Klijn J.G., Peters H.A., Foekens J.A. The MTT tetrazolium salt assay scrutinized: How to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J. Clin. Chem. Clin. Biochem. 1995;33:813–823. doi: 10.1515/cclm.1995.33.11.813. PubMed DOI

Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987;162:156–159. doi: 10.1016/0003-2697(87)90021-2. PubMed DOI

Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45. doi: 10.1093/nar/29.9.e45. PubMed DOI PMC

Kollinerova S., Dostal Z., Modriansky M. MicroRNA hsa-miR-29b potentiates etoposide toxicity in HeLa cells via down-regulation of Mcl-1. Toxicol. Vitr. 2017;40:289–296. doi: 10.1016/j.tiv.2017.02.005. PubMed DOI

Zheng Y.B., Luo H.P., Shi Q., Hao Z.N., Ding Y., Wang Q.S., Li S.B., Xiao G.C., Tong S.L. miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2. World J. Gastroenterol. 2014;20:6515–6522. doi: 10.3748/wjg.v20.i21.6515. PubMed DOI PMC

Zhou D.D., Wang X., Wang Y., Xiang X.J., Liang Z.C., Zhou Y., Xu A., Bi C.H., Zhang L. MicroRNA-145 inhibits hepatic stellate cell activation and proliferation by targeting ZEB2 through Wnt/beta-catenin pathway. Mol. Immunol. 2016;75:151–160. doi: 10.1016/j.molimm.2016.05.018. PubMed DOI

Kim T., Veronese A., Pichiorri F., Lee T.J., Jeon Y.J., Volinia S., Pineau P., Marchio A., Palatini J., Suh S.S., et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 2011;208:875–883. doi: 10.1084/jem.20110235. PubMed DOI PMC